Implications on emergence of antimicrobial resistance as a critical aspect in the design of oral sustained release delivery systems of antimicrobials

Pharmaceutical Research

Volumn 25, Issue 3, 2008, Pages 667-671

  Hoffman, Amnon ^a   Horwitz, Ehud ^a,b   Hess, Shmuel ^a   Cohen Poradosu, Ronit ^b   Kleinberg, Lilach ^a   Edelberg, Anna ^a   Shapiro, Mervyn ^b  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

lactam antibiotic; Antimicrobial resistance; Colonic microflora; Delayed action preparations; Oral dosage form

Indexed keywords

AMOXICILLIN; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GROWTH; COLON; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG STRUCTURE; FECES ANALYSIS; MALE; MICROFLORA; NONHUMAN; PRIORITY JOURNAL; RAT; SUSTAINED RELEASE PREPARATION;

ADMINISTRATION, ORAL; AMOXICILLIN; ANIMALS; ANTI-INFECTIVE AGENTS; BETA-LACTAMASES; CHEMISTRY, PHARMACEUTICAL; COLON; COLONY COUNT, MICROBIAL; DELAYED-ACTION PREPARATIONS; DRUG COMPOUNDING; DRUG DESIGN; DRUG RESISTANCE, BACTERIAL; FECES; GASTROINTESTINAL TRANSIT; ILEUM; INTESTINAL ABSORPTION; INTESTINES; INTUBATION, GASTROINTESTINAL; MALE; RATS; RATS, WISTAR; TIME FACTORS;

EID: 40549100072     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-007-9373-6     Document Type: Article

References (34)

1. A. Hoffman. Pharmacodynamic aspects of sustained-release formulations. Adv. Drug Deliv. Rev. 33:185-199 (1998).
2. A. Hoffman, and D. Stepensky. Pharmacodynamic aspects of modes of drug administration for optimization of drug therapy. Crit. Rev. Ther. Drug Carr. Syst. 16:571-639 (1999).
3. A. Nolting and H. Derendorf. Pharmacokinetic/pharmacodynamic modeling of antibiotics. In H. Derendorf, and G. Hochhaus (eds.), Handbook of Pharmacokinetic/Pharmacodynamic Correlation. CRC, Boca Raton, FL, 1995, pp. 363-388.
4. C. W. Wester, L. Durairaj, A. T. Evans, D. N. Schwartz, S. Husain, and E. Martinez. Antibiotic resistance-a survey of physician perceptions. Arch. Intern. Med. 162(19):2210-2216 (2002).
5. R. Chandra, P. Liu, J. D. Breen, J. Fisher, C. Xie, R. LaBadie, R. J. Benner, L. J. Benincosa, and A. Sharma. Clinical pharmacokinetics and gastrointestinal tolerability of a novel extended-release microsphere formulation of azithromycin. Clin. Pharmacokinet. 46(3):247-259 (2007).
6. A. Hoffman, H. D. Danenberg, I. Katzhendler, R. Shuval, D. Gilhar, and M. Friedman. Pharmacodynamic and pharmacokinetic rationales for the development of an oral controlled-release amoxicillin dosage form. J. Control. Release 54:29-37 (1998).
7. W. H. Barr, E. M. Zola, E. L. Candler, S. M. Hwang, A. V. Tendolkar, R. Shamburek, B. Parker, and M. D. Hilty. Differential absorption of amoxicillin from the human small and large intestine. Clin. Pharmacol. Ther. 56(3):279-285 (1994).
8. D. Zarowny, R. Ogilvie, D. Tamblyn, C. MacLeod, and J. Ruedy. Pharmacokinetics of amoxicillin. Clin. Pharmacol. Ther. 16(6):1045-1051 (1974).
9. X. Cao, S. T. Gibbs, L. Fang, H. A. Miller, C. P. Landowski, H. C. Shin, H. Lennernas, Y. Zhong, G. L. Amidon, L. X. Yu, and D. Sun. Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm. Res. 23(8):1675-1686 (2006).
10. J. Harmoinen, S. Mentula, M. Heikkila, M. Van der Rest, P. J. Rajala-Schultz, C. J. Donskey, R. Frias, P. Kosi, N. Wickstrand, H. Jousimies-Somer, E. Westermarck, and K. Lindevall. Orally administered targeted recombinant beta lactamase prevents ampicillin-induced selective pressure on the gut microbiotica: a novel approach to reducing antimicrobial resistance. Antimicrob. Agents Chemother. 48:75-79 (2004).
11. U. Stiefel, J. Harmoinen, P. Koski, S. Kaariainen, N. Wickstrand, K. Lindevall, N. J. Pultz, R. A. Bonomo, M. S. Helfand, and C. J. Donskey. Orally administered recombinant metallo-β-lactamase preserves colonization resistance of piperacillin-tazobactam-treated mice. Antimicrob. Agents Chemother. 46(12):5190-5191 (2005).
12. E. Torok, T. Somogyi, K. Rutkai, L. Iglesias, and I. Bielsa. Fusidic acid suspension twice daily: a new treatment schedule for ski and soft tissue infection in children, with improved tolerability. J. Derm. Treat. 15(3):15-63 (2004).
13. E. Bergogne-Bérézin, and A. Bryskier. The suppository form of antibiotic administration: pharmacokinetics and clinical application. J. Antimicrob. Chemother. 43:177-185 (1999).
14. I. Tamai, T. Nakanishi, K. Hayashi, T. Terao, Y. Sai, T. Shiraga, K. Miyamoto, E. Takeda, H. Higashida, and A. Tsuji. The predominant contribution of oligopeptide transporter PepT1 to intestinal absorption of β-lactam antibiotics in the rat small intestine. J. Pharm. Pharmacol. 49:796-801 (1997).
15. A. H. Dantzig. Oral absorption of β-lactams by intestinal peptide transport proteins. Adv. Drug Deliv. Rev. 23(1-3):63-76 (1997).
16. V. H. Lee. Membrane transporters. Eur. J. Pharm. Sci. 11(suppl.2):S41-S50 (2000).
17. E. J. Vollaard, and H. A. L. Classener. Colonization resistance. Antimicrob. Agents Chemother. 38:409-414 (1994).
18. T. D. Luckey. Introduction to intestinal microecology. Am. J. Clin. Nutr. 25:1292-294 (1972).
19. C. E. Nord, L. Kager, and A. Heimdahl. Impact of antimicrobial agents on the microflora and the risk of infections. Am. J. Med. 76:99-106 (1984).
20. K. D. Hooker, and J. T. DiPiro. Effect of antimicrobial therapy on bowel flora. Clin. Pharm. 12:878-888 (1988).
21. C. E. Nord, and C. Edlund. Impact of antimicrobial agents on human intestinal microflora. J. Chemother. 2:218-237 (1990).
22. C. Edlund and C. E. Nord. Effect on the human normal microflora of oral antibiotics for treatment of urinary tract infections. J. Antimicrob. Chemother. 46(suppl. S1):41-48 (2000).
23. L. B. Rice. Antimicrobial resistance in gram-positive bacteria. Am. J. Infect. Control 34(5 Suppl.1):S11-S19 (2006).
24. R. Patel. Clinical impact of vancomycin-resistant Enterococci. J. Antimicrob. Chemother. 51(suppl.3):iii13-iii21 (2003).
25. S. E. Cosgrove. The relationship between antimicrobial resistance and patient outcomes: mortality length of hospital stay and health care costs. Clin. Infect. Dis. 42(suppl.2):S82-S89 (2006).
26. C. M. Kaye, A. Allen, S. Perry, M. McDonagh, M. Davy, K. Storm, N. Bird, and O. Dewit. The clinical pharmacokinetics of a new pharmacokinetically enhanced formulation of amoxicillin/Clavulanate. Clin. Ther. 23(4):578-584 (2001).
27. S. Sethi, J. Bretton, and B. Wynne. Efficacy and safety of pharmacokinetically enhanced amoxicillin-clavulanate at 2,000/125 milligrams twice daily for 5 Days versus amoxicillin-clavulanate at 875/125 milligrams twice daily for 7 days in the treatment of acute exacerbations of chronic bronchitis. Antimicrob. Agents Chemother. 49:153-160 (2005).
28. W. A. Craig. Overview of newer antimicrobial formulations for overcoming pneumococcal resistance. Am. J. Med. 117(Supp. 3A):S16-S22 (2004).
29. M. J. Darkes and G. M. Perry. Clarithromycin extended-release tablet: a review of its use in the management of respiratory tract infections. Am. J. Respir. Medicine 2(2):175-201 (2003).
30. M. A. Drehobl, M. C. De Salvo, D. E. Lewis, and J. D. Breen. Single-dose azithromycin microspheres vs. clarithromycin extended release for the treatment of mild-to-moderate community-acquired pneumonia in adults. Chest 128(4):2230-2237 (2005).
31. W. A. Craig. Postantibiotic effects and the dosing of macrolides, azalides, and streptogramins. In S. H. Zinner, L. S. Young, and J. F. Acar (eds.), Expanding Indications for the New Macrolides, Azalides and Streptogramins. Marcel Dekker, New York, 1997, pp. 27-38.
32. P. Cole. Pharmacologic and clinical comparison of cefaclor in immediate release capsule and extended-release tablet forms. Clin. Ther. 19:617-625 (1997).
33. Bayer Healthare, http://www.CiproXR.com (accessed 12/15/2006).
34. A. Hoffman, D. Stepensky, E. Lavy, S. Eyal, E. Klausner, and M. Friedman. Pharmacokinetic and pharmacodynamic aspects of gastroretentive dosage forms. Int. J. Pharm. 227(1-2):141-153 (2004).